Canaccord raised the firm’s price target on Illumina (ILMN) to $112 from $105 and keeps a Hold rating on the shares. The firm said they reported 3Q25 results that were ahead of its estimates and FactSet consensus. The company shipped more NovaSeq X instruments than 2Q25 which was relatively in line with year-earlier levels. Illumina’s clinical consumables revenue continued to accelerate, increasing to +12% y/y as clinical customers transition to the NovaSeq X.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $100 from $95 at Barclays
- Illumina Reports Steady Q3 2025 Earnings
- Illumina’s Hold Rating: Balancing Growth Potential with Competitive and Financial Challenges
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Illumina reports Q3 adjusted EPS $1.34, consensus $1.17